Want to see IN:KREBSBIO full AI Analyst Report?
Top Page
Krebs Biochemicals & Industries Ltd.
(KREBSBIO)
Select Model
Select Model
Rating:49Neutral
Price Target:
₹69.00
▼(-2.82% Downside)
Action:Reiterated
Date:10/02/26
The score is held down primarily by weak financial performance (recurring losses, negative equity, and ongoing negative free cash flow), which outweighs the bullish technical setup. Technical momentum is strong but looks extended (high RSI), while valuation is challenged by losses and a negative P/E with no dividend yield data to support the case.
Positive Factors
Gross Margin Recovery
The return to positive gross margin indicates that product economics improved from earlier periods, potentially through better pricing, input-cost control, yields, or utilization. However, this benefit remains incomplete because it has not yet produced sustainable operating or net profitability.
Negative Factors
Persistent Net Losses
Persistent operating and net losses show that the company’s current revenue base and cost structure are not generating sustainable earnings. The latest approximately 71% net margin loss is especially severe, limiting internal funding capacity and making any turnaround dependent on meaningful operational improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross Margin Recovery
The return to positive gross margin indicates that product economics improved from earlier periods, potentially through better pricing, input-cost control, yields, or utilization. However, this benefit remains incomplete because it has not yet produced sustainable operating or net profitability.
Read all positive factors
Krebs Biochemicals & Industries Ltd. (KREBSBIO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.27B
Dividend YieldN/A
Average Volume (3M)2.83K
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue Growth-29.72%
EPS Growth47.98%
CountryIN
Employees142
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-6.54
Shares Outstanding21,560,587
10 Day Avg. Volume1,150
30 Day Avg. Volume2,825
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-0.53
Price to Sales (P/S)3.61
P/FCF Ratio-7.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Krebs Biochemicals & Industries Ltd. Business Overview & Revenue Model
Company Description
Established in 1991 and headquartered in Hyderabad, India, Krebs Biochemicals & Industries Limited primarily focuses on the production and distribution of active pharmaceutical ingredients (APIs) across India. The company also innovates by develop...
How the Company Makes Money
KREBSBIO primarily makes money by manufacturing chemical products and selling them to customers, generating revenue from product sales (typically recognized upon dispatch/delivery under customer contracts). Its earnings are driven by (a) sales vol...
Krebs Biochemicals & Industries Ltd. Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 252.34M | 237.32M | 433.12M | 504.21M | 521.34M | 597.03M |
| Gross Profit | 122.20M | 65.30M | 377.56M | -108.75M | 244.19M | -57.64M |
| EBITDA | -5.21M | -34.24M | -143.21M | -82.73M | -151.62M | -328.46M |
| Net Income | -140.94M | -169.33M | -269.39M | -197.28M | -246.92M | -445.27M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 1.63B | 1.69B | 1.78B | 1.75B | 1.90B |
| Cash, Cash Equivalents and Short-Term Investments | 1.29M | 1.29M | 3.38M | 1.37M | 858.00K | 1.01M |
| Total Debt | 0.00 | 2.25B | 2.12B | 2.39B | 1.83B | 1.88B |
| Total Liabilities | 1.63B | 3.26B | 3.15B | 2.97B | 2.74B | 2.65B |
| Stockholders Equity | -1.63B | -1.63B | -1.46B | -1.19B | -994.62M | -750.93M |
Cash Flow | ||||||
| Free Cash Flow | -37.27M | -121.78M | -114.54M | -70.50M | -355.84M | -407.36M |
| Operating Cash Flow | -16.76M | -90.06M | -78.91M | 23.65M | -247.13M | -172.16M |
| Investing Cash Flow | -21.83M | -36.36M | -49.70M | -78.17M | -126.45M | -229.00M |
| Financing Cash Flow | 38.44M | 126.30M | 128.65M | 55.64M | 373.43M | 395.06M |
Krebs Biochemicals & Industries Ltd. Technical Analysis
Positive
71.00
Price Trends
55.85
Positive
58.15
Positive
58.92
Positive
Market Momentum
0.74
Negative
59.13
Neutral
45.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KREBSBIO, the sentiment is Positive. The current price of 71 is above the 20-day moving average (MA) of 56.96, above the 50-day MA of 55.85, and above the 200-day MA of 58.92, indicating a bullish trend. The MACD of 0.74 indicates Negative momentum. The RSI at 59.13 is Neutral, neither overbought nor oversold. The STOCH value of 45.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:KREBSBIO.
Krebs Biochemicals & Industries Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹1.54B | 10.75 | ― | 0.70% | 4.29% | 2.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹1.27B | 35.42 | ― | ― | 0.46% | -83.31% | |
49 Neutral | ₹1.27B | -9.20 | ― | ― | -29.72% | 47.98% | |
49 Neutral | ₹1.78B | 24.13 | ― | 1.09% | 13.51% | -14.80% | |
47 Neutral | ₹517.83M | 102.74 | ― | ― | 9.31% | -82.71% | |
45 Neutral | ₹451.88M | -0.26 | ― | 0.67% | -39.80% | -452.04% |
* General Sector Average
IN:KREBSBIO
Krebs Biochemicals & Industries Ltd.
60.30
-13.35
-18.13%
IN:ALPA
Alpa Laboratories Limited
59.54
-30.20
-33.65%
IN:BALPHARMA
Bal Pharma Limited
109.28
27.11
32.99%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
30.31
-10.70
-26.09%
IN:PAR
Par Drugs and Chemicals Limited
126.64
21.72
20.70%
IN:VIVIMEDLAB
Vivimed Labs Limited
5.35
0.45
9.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.